No Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Adolescents by Franke, Maximilian et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
No Association of Variants of the NPY-System With Obsessive-Compulsive
Disorder in Children and Adolescents
Franke, Maximilian; Conzelmann, Annette; Grünblatt, Edna; Werling, Anna M; Spieles, Helen;
Wewetzer, Christoph; Warnke, Andreas; Romanos, Marcel; Walitza, Susanne; Renner, Tobias J
Abstract: Obsessive-compulsive disorder (OCD) causes severe distress and is therefore counted by the
World Health Organisation (WHO) as one of the 10 most impairing illnesses. There is evidence for a
strong genetic underpinning especially in early onset OCD (eoOCD). Though several genes involved in
neurotransmission have been reported as candidates, there is still a need to identify new pathways. In
this study, we focussed on genetic variants of the Neuropeptide Y (NPY) system. NPY is one of the
most abundant neuropeptides in the human brain with emerging evidence of capacity to modulate stress
response, which is of high relevance in OCD. We focussed on tag-SNPs of NPY and its receptor gene
NPY1R in a family-based approach. The sample comprised 86 patients (children and adolescents) with
eoOCD with both their biological parents. However, this first study on genetic variants of the NPY-
system could not confirm the association between the investigated SNPs and eoOCD. Based on the small
sample size results have to be interpreted as preliminary and should be replicated in larger samples.
However, also in an additional GWAS analysis in a large sample, we could not observe an associations
between NPY and OCD. Overall, these preliminary results point to a minor role of NPY on the stress
response of OCD.
DOI: https://doi.org/10.3389/fnmol.2019.00112
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-170738
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Franke, Maximilian; Conzelmann, Annette; Grünblatt, Edna; Werling, Anna M; Spieles, Helen; Wewet-
zer, Christoph; Warnke, Andreas; Romanos, Marcel; Walitza, Susanne; Renner, Tobias J (2019). No
Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Ado-
lescents. Frontiers in Molecular Neuroscience, 12:112.
DOI: https://doi.org/10.3389/fnmol.2019.00112
BRIEF RESEARCH REPORT
published: 03 May 2019
doi: 10.3389/fnmol.2019.00112
Edited by:
Ildikó Rácz,
Universitätsklinikum Bonn, Germany
Reviewed by:
Subhrangshu Guhathakurta,
University of Central Florida,
United States
Muddanna Sakkattu Rao,
Kuwait University, Kuwait
*Correspondence:
Tobias J. Renner
tobias.renner@med.uni-tuebingen.de
Received: 31 July 2018
Accepted: 17 April 2019
Published: 03 May 2019
Citation:
Franke M, Conzelmann A,
Grünblatt E, Werling AM, Spieles H,
Wewetzer C, Warnke A, Romanos M,
Walitza S and Renner TJ (2019) No
Association of Variants of the
NPY-System With
Obsessive-Compulsive Disorder in
Children and Adolescents.
Front. Mol. Neurosci. 12:112.
doi: 10.3389/fnmol.2019.00112
No Association of Variants of the
NPY-System With
Obsessive-Compulsive Disorder
in Children and Adolescents
Maximilian Franke1, Annette Conzelmann2, Edna Grünblatt3, Anna M. Werling3,
Helen Spieles2, Christoph Wewetzer4, Andreas Warnke1, Marcel Romanos1,
Susanne Walitza3 and Tobias J. Renner1,2*
1Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg,
Germany, 2Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Tübingen,
Tübingen, Germany, 3University Hospital of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland,
4Department of Child and Adolescent Psychiatry and Psychotherapy, Kliniken der Stadt Köln, Cologne, Germany
Obsessive-compulsive disorder (OCD) causes severe distress and is therefore counted
by the World Health Organisation (WHO) as one of the 10 most impairing illnesses.
There is evidence for a strong genetic underpinning especially in early onset OCD
(eoOCD). Though several genes involved in neurotransmission have been reported as
candidates, there is still a need to identify new pathways. In this study, we focussed on
genetic variants of the Neuropeptide Y (NPY) system. NPY is one of the most abundant
neuropeptides in the human brain with emerging evidence of capacity to modulate stress
response, which is of high relevance in OCD. We focussed on tag-SNPs of NPY and its
receptor gene NPY1R in a family-based approach. The sample comprised 86 patients
(children and adolescents) with eoOCD with both their biological parents. However, this
first study on genetic variants of the NPY-system could not confirm the association
between the investigated SNPs and eoOCD. Based on the small sample size results have
to be interpreted as preliminary and should be replicated in larger samples. However, also
in an additional GWAS analysis in a large sample, we could not observe an associations
between NPY and OCD. Overall, these preliminary results point to a minor role of NPY
on the stress response of OCD.
Keywords: NPY, obsessive-compulsive, children, anxiety, neuropeptide
INTRODUCTION
Obsessive-compulsive disorder (OCD) has a life-time prevalence of 2%–3.3%, both in adults and
children and has its peaks of onset around 12 years (early onset OCD, eoOCD) and in early
adulthood (late onset). The occurring obsessions/compulsions are interfering significantly with
the patients’ everyday life and cause severe distress and anxiety. Additionally, 75% of the patients
have at least one comorbidity. In eoOCD these are in particular attention deficit hyperactivity
disorder, major depression and anxiety disorders (Fireman et al., 2001). OCD is the fourth most
psychiatric disorder and due to its frequently severe impact on affected patients’ lives, the World
Health Organisation (WHO) counts OCD to the 10 most impairing illnesses (Karno et al., 1988;
Weissman et al., 1994; Lopez and Murray, 1998).
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Evidence for a strong genetic component in the development
of OCD derives from twin and family genetic studies as well
as segregation analyses. Prevalence in first-degree relatives of
OCD patients is about four times increased and even about
eight times higher in eoOCD patients (Pauls et al., 1995;
Alsobrook et al., 1999; Hanna et al., 2005). A higher familial
load of eoOCD was observed in general, suggesting a greater
importance of genetic factors (Pauls et al., 1995; Nestadt et al.,
2000). In the search for genetic underpinnings in OCD, mainly
genes of the serotonergic system were focussed, driven by
the pharmacological effectivity of selective serotonin reuptake
inhibitors (SSRIs). Several studies aimed at the gene encoding
the serotonin-transporter (Bengel et al., 1999). Nonetheless,
study results are heterogeneous and replications and a recent
meta-analysis revealed a rather low effect size for the serotonin
transporter (Walitza et al., 2014). Further, evidence emerged that
the glutamate system is involved inOCD andmight be a potential
alternative pharmacological treatment target, especially since the
association with the glutamate receptor gene SLC1A1 has been
replicated in several studies (Wendland et al., 2009; Stewart et al.,
2013; Grados et al., 2015). However, variance explained by the
known candidates is still rather small and given the clinical
complexity of OCD there is an understanding that many genes
are involved in the disease’s pathogenesis.
In the search for further neuronal messengers involved,
the Neuropeptide Y (NPY) is a highly interesting candidate
(Tatemoto et al., 1982). It is one of the most abundant
neuropeptides in the human brain and has multiple
regulating effects in the nervous system. NPY, long known
as a neuropeptide modulating feeding behavior and energy
homeostasis (Morton and Schwartz, 2001), has been reported
influencing neuronal processes relevant in psychiatric disorders.
For instance, there is a rising evidence that the NPY-system
including the NPY-receptors is involved in the development of
alcohol and drug dependency (NPY1R), stress coping (NPY1R,
NPY2R, NPY5R) and anxiolysis (NPY1R, NPY2R; Gerald
et al., 1996; Movafagh et al., 2006; Hirsch and Zukowska, 2012;
Pedragosa-Badia et al., 2013). Especially regulation of stress
and anxiety levels are crucial elements in the development
and maintenance of OCD. Patients affected by OCD suffer
fear and simultaneously triggered stress when they experience
the feeling ‘‘something is not in order.’’ NPY is released
in many brain areas that participate in stress response.
These are, for example, the adrenergic and noradrenergic
(NA) neurons of the brainstem, the corticotropin-releasing
factor (CRF)-neurons of the nucleus paraventricularis, the
amygdala and the hypothalamus as well as an impact on the
hypothalamic-pituitary-adrenal (HPA)-axis (Heilig, 2004;
Alldredge, 2010). The NPY1R-receptor was shown to modulate
anxious behavior and stress which can be reversed by NPY
administration (Kormos and Gaszner, 2013). Interestingly,
there is also an interaction of NPY and the serotonergic
system (Diksic and Young, 2001; Pittenger and Bloch, 2014).
SSRI administration leads to a higher NPY release in stressed
depressive mice and a mediating role of NPY on SSRI effects
is discussed (Caberlotto et al., 1998; Redrobe et al., 2005;
Christiansen et al., 2011). This interplay of SSRI and NPY
showed for depression might be of relevance in OCD as well,
especially due to the high comorbidity rate of the two illnesses
(Torres et al., 2016).
Therefore, in this molecular genetic study, we aimed at the
NPY-system as a messenger system with potential influence on
the pathogenesis of eoOCD. Due to their previously reported
functions in the regulation of anxiety and stress, we focussed on
NPY and its receptorNPY1R in a family-based approach. Genetic
variants ofNPY andNPY1Rwere genotyped in a German family-
based sample. The present study is the first investigating genes of
the NPY-system in eoOCD.
MATERIALS AND METHODS
Subjects
All patients were recruited at the Department of Child and
Adolescent Psychiatry, Psychosomatics and Psychotherapy,
University Hospital Würzburg, Germany. Patients and parents
were all of Caucasian descent and agreed to participate in the
study. All participants and, in the case of minors, their parents,
gave written informed consent. The study was approved by the
Ethics Committees of the University of Würzburg.
Patients were included in the study after they had fulfilled the
diagnostic criteria for eoOCD according to DSM-IV (American
Psychiatric Association, 2000), which was valid at the time
of recruitment, and ICD-10 (Dilling, 2015). Patients and
parents were interviewed separately for childrens’ psychiatric
disorders with the German semi-structured clinical ‘‘Diagnostic
Interview for Psychiatric Disorders in Children and Adolescents’’
(DIPS; Schneider et al., 1995). Subsequently, the severity of
symptoms was assessed by the Childrens’ Yale-Brown Obsessive
Compulsive Scale (cY-BOCS; Goodman et al., 1989; Scahill
et al., 1997). Subjects with comorbid disorders were only
included when OCD was the main psychiatric diagnosis.
Senior clinicians or psychologists performed all interviews
and ratings.
Exclusion criteria were a lifetime history of psychotic
disorders, Tourette’s syndrome, autism spectrum disorders,
alcohol dependence or mental retardation (IQ ≤ 70).
The sample comprised 86 patients (children and adolescents)
with eoOCD and their parents. Fifty-one children were female,
35 were male. The patients’ mean age was 10.7 years (SD = 2.8) at
the onset of disease in a range from 3 to 15 years. In 32 patients
onset was earlier than the age of 10 years. Eleven patients
had tic-disorders as comorbidities. Further comorbidities as
depression, ADHD or anorexia nervosa existed frequently in
the patients’ medical histories but were not clinically relevant
at the time of study inclusion. The sample was part of previous
genetic analyses and described further in previous publications
(e.g., Walitza et al., 2008).
Based on a power analysis with alpha 0.05 and beta 0.80
(according to Neumann et al., 2014) a sample size of at least
N = 105 would have been required to unravel significant effects.
Therefore, we additionally analyzed associations of NPY and
OCD with the recent GWAS by Arnold et al. (2018).
To enlarge the sample size of OCD patients we used
the data of the most recent GWAS meta-analysis on OCD
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FIGURE 1 | Gene loci of Neuropetide Y (NPY, A) and NPY-receptor (NPY1R, B).
including 2,688 individuals affected by OCD and 7,037 controls
by the Psychiatric Genomics Consortium, and searched the
results for each of the SNPs investigated in our study. The
GWAS by the Psychiatric Genomics Consortium comprised
2,688 individuals affected by OCD and 7,037 controls.
The meta-analysis comprised children as well as adults
(Arnold et al., 2018).
Gene Loci
NPY and NPY1R SNPs chosen for this study were tag-SNPs
and previously published SNPs with reported influence on
psychiatric disorders. The latter were studied with regard
to stress-related diseases, as OCD is postulated to be, like
depression, ADHD and obesity (Peterson et al., 2001; Tiwari
et al., 2013). Tag-SNPs were determined using HaploViewr to
cover both genes completely on the basis of SNP data provided
by the International HapMap-Project (International HapMap
Consortium, 2003; Barrett et al., 2005; Figure 1). Tagger settings
included aminor allele frequency>0.1 and r2 = 0.9. Additionally,
SNPs known from previously published studies pertaining to
other disorders were included in the tagging process. For NPY,
SNPs rs5574, rs16124, rs16139, rs16147 were determined, and
SNPs rs9764, rs4691075, rs7687423 and rs10033119 were found
for NPY1R.
Genotyping
Genomic DNA was extracted from whole blood following
standard protocols. DNA was amplified by standard PCR using
specific reverse- and forward-primers for each of the eight SNPs.
After amplification genotypes were determined by enzymatic
digestion and gel-electrophoresis. Further detailed information
on primers and procedures is available upon request.
Statistics
Association between the included markers of NPY and NPY1R
and eoOCD was tested by the Transmission Disequilibrium
Test (TDT; Spielman et al., 1993). TDT was performed for all
eight SNPs using the software FamHAPr (Herold and Becker,
2008). A p-value < 0.05 was defined as the significance level.
Each of the trios was tested for the hypothesis that their tested
gene variants of either: (1) NPY or (2) NPY1R are associated
with eoOCD. The examination pattern used for this analysis
was a genotype-wise model considering every heterozygous
parental genotype separately and corresponds to a test of the
global null-hypothesis of transmission equilibrium of both alleles
in every parental genotype. All eight SNPs were checked for
Mendelian Errors which were exclusion criteria. Moreover, all
parental genotype distributions were tested for Hardy-Weinberg
equilibrium (HWI).
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RESULTS
In one of the NPY1R-SNPs, rs4691074, occurred a deviation
from the HWI (p = 0.04). The remaining seven SNPs were
unremarkable (p > 0.05). No transmission disequilibrium was
observed for the NPY-SNPs. The p-values exceeded the defined
significance level α (Table 1). For rs5574, 34 heterogeneous
parental couples could be examined (χ2(1) = 1.058; p = 0.303), for
rs16124, 85 (χ2(1) = 0.576; p = 0.448), for rs16139, 12 (χ
2
(1) = 0.333;
p = 0.564) and for rs16147, 76 (χ2(1) = 0.842; p = 0.359). Moreover,
no transmission disequilibrium could be assessed for theNPY1R-
SNPs. For rs9764, 72 heterogeneous parental couples could be
analyzed (χ2(1) = 0.000; p = 1.000), for rs4691075, 33 (χ
2
(1) = 1.485;
p = 0.223), for rs7687423, 89 (χ2(1) = 0.101; p = 0.75) and for
rs10033119, 14 (χ2(1) = 0.000; p = 1.000).
The GWAS meta-analysis also showed no association of any
NPY- nor NPY1R-SNPs with regard to the development of OCD
(Table 2).
DISCUSSION
This is the first molecular genetic study on potential functional
variants of the candidate gene NPY and its receptor NPY1R in
eoOCD. In this study, association was not detected. Thus, we
could not confirm a major role of the NPY system in OCD with
childhood onset.
As our number of trios was smaller than postulated by the
power-analysis, the negative outcome might foremost be due
to the sample size. That is why we used the data of the most
recent and aforementioned GWASmeta-analysis on OCD by the
Psychiatric Genomics Consortium, and searched the results for
the investigated SNPs. Though our sample was part of this meta-
analysis, a potential effect over a large sample including different
ages of onset might have been observable. However, also this
meta-analysis showed no association of any NPY- nor NPY1R-
SNPs (Arnold et al., 2018). Our study had been designed as a
family-based study to avoid stratification effects, nonetheless, a
case-control study, which had not been performed so far with
regard to the studied gene loci, would be highly interesting.
However, the NPY system, which is involved in stress
response, might still be of relevance in OCD subgroups, although
undetected due to the study design. The selected SNPs were
either already known from earlier studies to other stress-related
psychiatric disorders or tag-SNPs that were selected out of the
HapMap data with the help of the programme Haploviewr
(Barrett et al., 2005) in order to cover NPY and NPY1R.
TABLE 1 | Transmission Disequilibrium Test (TDT) results.
SNP Gene Allele T NT χ2(1) pTDT
rs5574 NPY 2 20 14 1.059 0.303
4 14 20
rs16124 NPY 3 39 46 0.576 0.448
4 46 39
rs16139 NPY 2 7 5 0.333 0.564
4 5 7
rs16147 NPY 2 34 42 0.842 0.359
4 42 34
rs9764 NPY1R 1 36 36 0.000 1.000
3 36 36
rs4691075 NPY1R 1 20 13 1.485 0.223
3 13 20
rs7687423 NPY1R 2 46 43 0.101 0.750
4 43 46
rs10033119 NPY1R 2 7 7 0.000 1.000
4 7 7
Note: Column 1 lists the SNP names, column 2 the correspondent gene, column 3 shows the present allele: 1 equal to adenine, 2 equal to cytosine, 3 equal to guanine, 4 equal to
thymine. Column 4 shows the number of transmissions (T) for each gene, column 5 shows the number of non-transmitted (NT) alleles. Column 6 represents the chi square value,
column 7 the p-value.
TABLE 2 | Meta-analysis results.
Chr. SNP bp A1 A2 Info OR SE p
7 rs5574 24329133 T C 0.9750 0.967152 0.0949 0.7248
7 rs16124 24331799 T G 0.9735 1.00944 0.0335 0.7802
7 rs16139 24324879 T C 0.9737 0.983144 0.0335 0.6112
7 rs16147 24323410 T C 0.9720 1.01572 0.0335 0.6421
4 rs9764 164245405 T C 1.0030 1.03345 0.0382 0.3881
4 rs4691075 164249485 T C 0.9948 0.937255 0.0504 0.1991
4 rs7687423 164250797 A G 0.9800 1.001 0.0347 0.9766
4 rs10033119 164245854 A G 0.8709 0.962809 0.0851 0.6562
Note: Column 1 lists the respective chromosomes (hg 19), column 2 the correspondent marker name, column 3 shows the base pair location (hg 19), column 4 shows the reference
allele for OR (may or may not be minor allele), column 5 the alternative allele. Column 6 represents the imputation information score, column 7 the Odds ratio for the effect of the
A1 allele, column 8 the standard error of the log(OR) and column 9 the p-value for the association test in the meta-analysis.
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Nonetheless, the selected SNPs are infrequent in the population,
thus statistically evaluable transmissions in the sample were
rather small.
Reflecting the NPY-system, other effectors like the
Y2-receptor and the Y5-receptor might also be valuable targets
in OCD. The Y1-receptor was the first choice for this study due
to its various anxiolytic and stress-reducing effects and its wide
spread dissemination in stress regulating brain regions. Anxious
behavior and stress can be reversed with NPY administration
(Kormos and Gaszner, 2013). Nevertheless, the influence of the
remaining receptors should not be excluded a priori. Especially
the Y5-receptor shares a similar effect spectrum with the tested
Y1 (Kormos and Gaszner, 2013). Even though its role is not
fully understood yet, an effect on the fear and stress system
seems to be obvious and further research worthwhile. The
Y2-receptor, however, could indirectly influence the delicate
equilibrium of neurotransmission with its impact on the release
of other neurotransmitters (Upadhya et al., 2009; Kormos and
Gaszner, 2013). A reduced inhibition of glutamate release,
for example, could be a correlate for the increased thalamic
and striatal glutamate activity in untreated OCD-children
and could explain the upregulation of Y2-receptors in a
state of anxiety in the mouse model (Leckman et al., 1997;
Upadhya et al., 2009).
Our sample consists of children and adolescents only,
resembling an OCD subgroup with early onset and a significant
number of children with an onset before the age of 10 years.
A stronger impact of genetic factors is reported for eoOCD
and our sample might differ from adult samples regarding
genetic underpinnings and impact of life-events (Nestadt et al.,
2000; Walitza et al., 2008). The responsivity of the NPY system
after stress exposure during the development has been shown
in animal models and could be of higher relevance in failed
coping and development of OCD in adults (Serova et al., 2017;
Yam et al., 2017).
Moreover, comorbidities as e.g., ADHD or depression were
accepted in this study. Nonetheless, comorbidities in OCD
might indicate distinct neurobiological OCD subgroups with
divergent etiologies (Taurines et al., 2010). An analysis reflecting
the comorbidities was not applicable due to the sample size.
Especially an analysis regarding comorbidity with depression
would be of interest (Caberlotto et al., 1998; Redrobe et al., 2005;
Christiansen et al., 2011).
Due to the sample size, we were not able to examine an
influence of gender, which was reported for other candidate
genes in previous studies. In the meta-analyses of the glutamate
transporter gene SLC1A1, the SNP rs12682807 was found
associated only in male probands (Thiele et al., 1998; Arnold
et al., 2006; Wendland et al., 2009). Other genetic publications
also stated gender differences (Thiele et al., 1998; Dickel et al.,
2006; Canals et al., 2012). Gender differences are also found
in the clinical perspective with the prevalence of subclinical
OCD-symptoms twice as high in boys than in girls (Canals
et al., 2012). Furthermore, the two sexes differ in the clinical
manifestation which comprises an earlier age of onset as well
as a higher prevalence of symptoms belonging to the entity of
symmetry and ordering among males and increased symptoms
of cleanliness and washing among females (Bogetto et al., 1999;
Stewart et al., 2007).
Though the sample size was rather small for a genetic study,
regarding eoOCD it has a considerable size. Since the sample was
collected in one facility, it provides a clear stringency regarding a
precisely defined phenotype and restrictive exclusion of severe
comorbid disorders to assure the predominance of definite
OCD in contrast to obsessive-compulsive symptoms in other
psychiatric disorders.
In conclusion, our family-based study on genetic variants
of NPY and NPY1R could not confirm association with OCD
with childhood onset correlating with the outcomes for adult
NPY and OCD by Altemus et al. (1999). Unfortunately, there
is overall a paucity of studies on NPY and OCD and we
can only add another hint for non-existing significant effects.
We only know so far that NPY is involved in stress and
other anxiety disorders. Therefore, we hope that we could
deliver with our study a contribution to the question about
an association of NPY with OCD. The major impact of our
study is that we could show in our sample—and comprehending
the forementioned GWAS-data—that NPY effects on OCD
should be very small or not present. The very impact of
our study is a sample consisting of early onset patients and
therefore of fundamental impact on the database in this
specific subgroup. Moreover, the outcome has a meaning for
the understanding of the stress response in OCD in general
which might be different from other anxiety disorders with
an association to NPY. Indeed, in DSM V OCD is no
longer listed under anxiety disorders. If our null finding is
replicated in larger studies, we might conclude that NPY
has no effect on the stress response in OCD and probably
might also be a less valuable target for pharmacological
research in OCD.
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